Table 3.
Univariate and Multivariate Analysis of Factors for OS
| Variable | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) | P | Hazard Ratio (95% CI) | P | |
| Gender (male/female) | 0.505 (0.265–0.964) | 0.038 | 0.426 (0.217–0.833) | 0.013 |
| Age (<60 years/≥60 years) | 0.871 (0.601–1.261) | 0.464 | ||
| Liver cirrhosis (yes/no) | 0.971 (0.684–1.377) | 0.868 | ||
| TNMa stage (I–II/III–IV) | 1.383 (0.929–2.057) | 0.110 | ||
| Cell differentiation (poor/moderate-well) | 1.136 (0.798–1.618) | 0.480 | ||
| Microvascular invasion (positive/negative) | 1.530 (1.054–2.222) | 0.025 | 0.652 (0.447–0.950) | 0.026 |
| Tumor number (=1/≥2) | 1.113 (0.659–1.881) | 0.688 | ||
| HBsAgb (positive/negative) | 0.956 (0.625–1.464) | 0.837 | ||
| AFPc (≤7.00 ng/mL/>7.00 ng/mL) | 0.953 (0.669–1.358) | 0.791 | ||
| PTd (<14.35s/≥14.35s) | 1.324 (0.914–1.918) | 0.138 | ||
| ALT/ASTe (<0.568/≥0.568) | 1.673 (1.037–2.700) | 0.035 | 1.845 (1.093–3.114) | 0.022 |
| Fib-4f (<2.824/≥2.824) | 0.635 (0.440–0.916) | 0.015 | 0.737 (0.488–1.112) | 0.146 |
| GPRg (<0.205/≥0.205) | 0.584 (0.394–0.866) | 0.007 | 0.673 (0.443–1.021) | 0.063 |
| HALP scoreh (<54.132/≥54.132) | 1.527 (1.072–2.176) | 0.019 | 1.708 (1.192–2.448) | 0.004 |
| Treatment protocol (surgery only/combined treatment) | 1.913 (1.348–2.716) | <0.001 | 1.882 (1.321–2.681) | <0.001 |
Notes: aTumor node metastasis; bHepatitis B surface antigen; cAlpha-fetoprotein; dProthrombin time; eAlanine aminotransferase/aspartate aminotransferase; fFibrosis-4 score; gγ-glutamyl transpeptidase to platelet ratio; hHemoglobin, albumin, lymphocyte, and platelet.